Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 4/20 | 0.49 |
| ▸ | GPBAR1 | Q8TDU6 | 8/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.33 |
| ▸ | POLQ | O75417 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4259182 | 1.00 | TACR1 (0.49) | TACR1GPBAR1NOTUMCCR2DDR1 | |
| SCHEMBL4264358 | 0.93 | TACR1 (0.57) | TACR1GPBAR1CCR2 | |
| SCHEMBL493651 | 0.91 | TACR1 (0.48) | TACR1GPBAR1NOTUMCCR2DDR1 | |
| SCHEMBL3766497 | 0.91 | TACR1 (0.48) | TACR1GPBAR1NOTUMCCR2DDR1 | |
| SCHEMBL3226841 | 0.90 | TACR1 (0.37) | TACR1HDAC6 | |
| SCHEMBL6002099 | 0.90 | TACR1 (0.37) | TACR1HDAC6 | |
| SCHEMBL10019606 | 0.89 | TACR1 (0.50) | TACR1GPBAR1CCR2 | |
| SCHEMBL5327531 | 0.88 | TACR1 (0.49) | TACR1GPBAR1CCR2DDR1 | |
| SCHEMBL5435321 | 0.88 | TACR1 (0.49) | TACR1GPBAR1CCR2DDR1 | |
| SCHEMBL14136104 | 0.87 | TACR1 (0.48) | TACR1GPBAR1CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311713-A1 | Novel Azetidine Compounds Useful in the Treatment of Functional Gastrointestinal Disorders, Ibs and Functional Dyspepsia | ASTRAZENECA AB (SE) | 2010-12-09 | — | — | US | claimed |
| US-20100069346-A1 | New Azetidine Derivatives as Neurokinin Receptor Antagonists for the Treatment of Gastrointestinal Diseases | ALBIREO AB (SE) | 2010-03-18 | — | — | US | claimed |
| CN-101316846-A | Novel azetidine compounds useful in the treatment of functional gastrointestinal disorders, IBS and functional dyspepsia | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | CN | claimed |
| CN-101208327-A | New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases | ASTRAZENECA AB (SE) | 2008-06-25 | — | — | CN | claimed |
| CN-101203511-A | New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases | ASTRAZENECA AB (SE) | 2008-06-18 | — | — | CN | claimed |
| CN-104873482-B | Pharmaceutical composition for resisting chronic heart failure | 青岛市市立医院 | 2017-12-01 | — | — | CN | disclosed |
| CN-104873482-A | Pharmaceutical composition for resisting chronic heart failure | QINGDAO MUNICIPAL HOSPITAL | 2015-09-02 | — | — | CN | disclosed |
| EP-1940845-B1 | NOVEL AZETIDINE COMPOUNDS USEFUL IN THE TREATMENT OF FUNCTIONAL GASTROINTESTINAL DISORDERS, IBS AND FUNCTIONAL DYSPEPSIA | ALBIREO AB (SE) | 2013-06-12 | — | — | EP | disclosed |
| US-8288370-B2 | Substituted azetidine compounds of formula (I) useful in the treatment of functional gastrointestinal disorders, IBS, and functional dyspepsia | ALBIREO AB (SE) | 2012-10-16 | — | — | US | disclosed |
| US-8288370-B2 | Substituted azetidine compounds of formula (I) useful in the treatment of functional gastrointestinal disorders, IBS, and functional dyspepsia | ALBIREO AB (SE) | 2012-10-16 | — | — | US | disclosed |
| US-8288370-B2 | Substituted azetidine compounds of formula (I) useful in the treatment of functional gastrointestinal disorders, IBS, and functional dyspepsia | ALBIREO AB (SE) | 2012-10-16 | — | — | US | disclosed |
| US-8106208-B2 | Benzamide compounds that act as NK receptor antagonists | ALBIREO AB (SE) | 2012-01-31 | — | — | US | disclosed |
| WO-2007136324-A1 | 1- [ (4- [BENZOYL (METHYL) AMINO] -3- (PHENYL) BUTYL] AZETIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS 1 | ALBIREO AB (SE) | 2007-11-29 | — | — | WO | disclosed |
| US-20070270398-A1 | New Compounds III | ALBIREO AB (SE) | 2007-11-22 | — | — | US | disclosed |
| US-20070270398-A1 | New Compounds III | ALBIREO AB (SE) | 2007-11-22 | — | — | US | disclosed |
| US-20070270398-A1 | New Compounds III | ALBIREO AB (SE) | 2007-11-22 | — | — | US | disclosed |
| WO-2007037743-A1 | NOVEL AZETIDINE COMPOUNDS USEFUL IN THE TREATMENT OF FUNCTIONAL GASTROINTESTINAL DISORDERS, IBS AND FUNCTIONAL DYSPEPSIA | ASTRAZENECA AB (SE) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007037743-A1 | NOVEL AZETIDINE COMPOUNDS USEFUL IN THE TREATMENT OF FUNCTIONAL GASTROINTESTINAL DISORDERS, IBS AND FUNCTIONAL DYSPEPSIA | ASTRAZENECA AB (SE) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007037742-A1 | NOVEL AZETIDINE COMPOUNDS USEFUL IN THE TREATMENT OF FUNCTIONAL GASTROINTESTINAL DISORDERS, IBS AND FUNCTIONAL DYSPEPSIA | ASTRAZENECA AB (SE) | 2007-04-05 | — | — | WO | disclosed |
| WO-2006137791-A1 | NEW AZETIDINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311713-A1 | Novel Azetidine Compounds Useful in the Treatment of Functional Gastrointestinal Disorders, Ibs and Functional Dyspepsia | NISCH, BDKRB2, VIP | TACR1 6/4885GPBAR1 186/4885NOTUM 3296/4885 |
| US-20100069346-A1 | New Azetidine Derivatives as Neurokinin Receptor Antagonists for the Treatment of Gastrointestinal Diseases | GIPR, HRH2, BDKRB2 | TACR1 8/4885GPBAR1 82/4885NOTUM 3459/4885 |
| US-20070270398-A1 | New Compounds III | CYP11B2, CYP11B1, SDHA | TACR1 154/4885GPBAR1 195/4885NOTUM 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.